Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Even transient hyperglycemia has been shown to induce epigenetic modifications that sustain NF-B expression and promote ECD even after the restoration of normoglycemia [169]
A once-weekly dosing interval may offer several practical advantages, including: Potentially improved patient adherence compared with daily injections an association observed with other once-weekly incretin therapies, though direct adherence data for retatrutide are not yet available Relatively stable plasma drug levels between doses, which may help reduce the peaks and troughs that can contribute to side effects Consistent pharmacodynamic effects throughout the week, supporting sustained appetite suppression and metabolic activity In Phase 2 trials (Jastreboff et al., NEJM , 2023), retatrutide was studied across a range of doses up to 12 mg once weekly, with structured dose-escalation protocols used to improve tolerability a strategy commonly employed with incretin-based therapies to minimise gastrointestinal side effects such as nausea, vomiting, and diarrhoea during initiation
CLINICAL DOSING: 5mg per day
Older Adults: Standards of Care in Diabetes2023
US$ 23.79
US$ 28.34
US$ 20.65
US$ 22.59
